Global MethicillinResistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product(Instruments, Reagents & Kits), By Test Type (Immunodiagnostic Test andMolecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories,and Academic and Research Institute), and By Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa), is estimated to bevalued at US$ 211.3 million in 2020 and is expected to exhibit aCAGR of 10.5% during the forecast period (2020-2027), as highlighted in a newreport published by Coherent Market Insights.
The increasing number of productapprovals and launches, adoption of methicillin resistant staphylococcus aureus(MRSA) testing systems, and mergers and acquisitions by key players are themajor factors that are expected to drive growth of the Methicillin ResistantStaphylococcus Aureus (MRSA) Testing Systems market during the forecast period.
Product approvals by regulatorybodies are expected drive growth of the methicillin resistant Staphylococcusaureus (MRSA) testing systems market during the forecast period. For instance,in December 2019, the US Food and Drug Administration (FDA) granted marketingapproval for Roche Molecular Systems’ cobas vivoDx MRSA, a diagnostic test thatdetects colonisation of Methicillin-resistant Staphylococcus aureus (MRSA)bacteria. The cobas vivoDx MRSA test uses a new bacteriophage technology basedon bioluminescence to detect MRSA from nasal swab samples in as less as 5 hourscompared to 24-48 hours for conventional culture. The cobas vivoDx MRSAdiagnostic test may allow healthcare professionals to evaluate patients forcolonization with MRSA bacteria more quickly than traditional culture-basedtechniques.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3803
Key players are focused ondevelopment and launch of new methicillin resistant staphylococcus aureus(MRSA) testing systems in the market which is expected to contributesignificantly to the methicillin resistant staphylococcus aureus (MRSA) testingsystems market growth. For instance, in June 2019, Spindiag, a medtech startupcompany based in Germany, announced that it had expanded financing of its firstSeries A funding for MRSA testing systems. A proprietary microfluidictechnology was first researched at the company’s main institute. Spindiag isdeveloping a sustainable platform to diagnose infections and as a firstproduct, a rapid test for multidrug-resistant bacteria. Furthermore, theadditional money will enable industrializing the production and securing CE-IVDapproval for the EU market of an MRSA (methicillin-resistant Staphylococcusaureus) rapid test is planned for launch in 2020. Spindiag intends to use US$4.3 million to execute its market entry in Europe in 2020.
The increasing awareness aboutmethicillin resistant staphylococcus aureus (MRSA) infections and preventionefforts by hospitals, governments, and other organizations is expected toaccelerate the methicillin resistant staphylococcus aureus (MRSA) testingsystems market growth in the near future. The U.S. Department of Health andHuman Services and Centers for Disease Control and Prevention are working withhealthcare facilities to meet the goals in the 2013 National Action Plan toPrevent Healthcare-Associated Infections and reduce bloodstream infectionscaused by MRSA by 50% by 2020 using the 2015 baseline.
Browse 35 Market Data Tables and29 Figures spread through 177 Pages and in-depth TOC on Global MethicillinResistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product(Instruments, Reagents & Kits), By Test Type (Immunodiagnostic Test, andMolecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories,and Academic and Research Institute), and By Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa) - Forecast to2027"
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/methicillin-resistant-staphylococcus-aureus-testing-systems-market-3803
Several market players arefocused on acquisitions and mergers to expand their product portfolio and gaina maximum share in the market. For instance, in September 2017, AbbottLaboratories announced that they have completed the acquisition of Alere, Inc. forUS$ 5.3 billion. With the acquisition of Alere, the company also obtained thesubsidiary Arriva Medical, which is the largest mail-order diabetic supplier.This acquisition has established Abbott as the global leader in point of caretesting in vitro diagnostics market and further strengthened the company'sdiagnostics presence.
Key Takeaways of the MethicillinResistant Staphylococcus Aureus (MRSA) testing systems market:
The methicillin resistantstaphylococcus aureus (MRSA) testing systems market is expected to exhibit aCAGR of xx% during the forecast period (2020-2027) owing to increasing productapprovals and product launches.
Among product type, theinstruments segment is expected to hold a major revenue share in 2027 owing tothe increasing product approvals and launches. For instance, in March 2014,AdvanDx announced that it has submitted its new mecA XpressFISH test to theU.S. Food and Drug Administration for 510(k) clearance for the rapid detectionof methicillin-resistant Staphylococcus aureus (MRSA) from S. aureus positiveblood cultures. This assay will provide physicians with a new way to rapidlyidentify MRSA enabling them to implement appropriate treatment for patientswith bloodstream infections.
Major players operating in themethicillin resistant Staphylococcus aureus (MRSA) testing systems market areF.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH,BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, AbbottLaboratories, Puritan Medical Products, Diatherix Eurofins, LLC, ArlingtonScientific Inc., AdvanDx, Genspeed Biotech GmbH, Cepheid Inc., LuminexCorporation, and R-Biopharm AG.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3803
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
